<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Variety of therapeutic agents used in clinical trials registered to treat COVID-19</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="2">Group</th>
    <th rowspan="2">Therapeutic agent</th>
    <th colspan="4">Example of clinical trials registered at 
     <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link>
    </th>
   </tr>
   <tr>
    <th>CT number</th>
    <th>Country</th>
    <th>Recruitment status</th>
    <th>Phase</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="8">Serum</td>
    <td>Convalescent serum</td>
    <td>NCT04327349</td>
    <td>Iran</td>
    <td>Enrolling by invitation</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td rowspan="4">Convalescent plasma</td>
    <td>NCT04372979</td>
    <td>France</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>NCT04343755</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04363034</td>
    <td>USA</td>
    <td>Available</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>NCT04333355</td>
    <td>Mexico</td>
    <td>Recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td>Inactivated convalescent plasma</td>
    <td>NCT04292340</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td>Immunoglobulin of cured patients</td>
    <td>NCT04264858</td>
    <td>China</td>
    <td>Not yet recruiting</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>Immunoglobulins obtained with DFPP</td>
    <td>NCT04346589</td>
    <td>Italy</td>
    <td>Recruiting</td>
    <td>NA</td>
   </tr>
   <tr>
    <td rowspan="30">Monoclonal antibodies</td>
    <td rowspan="5">Tocilizumab</td>
    <td>NCT04322773</td>
    <td>Denmark</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04317092</td>
    <td>Italy</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04331795</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04377659</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04345445</td>
    <td>Malaysia</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td rowspan="2">Sarilumab</td>
    <td>NCT04315298</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td>NCT04324073</td>
    <td>France</td>
    <td>Recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td>Avdoralimab</td>
    <td>NCT04371367</td>
    <td>France</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Gimsilumab</td>
    <td>NCT04351243</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Siltuximab</td>
    <td>NCT04329650</td>
    <td>Spain</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Bevacizumab</td>
    <td>NCT04275414</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td>Eculizumab</td>
    <td>NCT04288713</td>
    <td>USA</td>
    <td>Available</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td>Emapalumab</td>
    <td>NCT04324021</td>
    <td>Sweden</td>
    <td>Recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td>Clazakizumab</td>
    <td>NCT04381052</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td rowspan="2">Canakinumab</td>
    <td>NCT04362813</td>
    <td>USA, Spain, UK</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>NCT04348448</td>
    <td>Italy</td>
    <td>Not yet recruiting</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>Olokizumab</td>
    <td>NCT04380519</td>
    <td>Russia</td>
    <td>Recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td>Otilimab</td>
    <td>NCT04376684</td>
    <td>UK</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Sirukumab</td>
    <td>NCT04380961</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Emapalumab</td>
    <td>NCT04324021</td>
    <td>Sweden</td>
    <td>Recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td>Lenzilumab</td>
    <td>NCT04351152</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Leronlimab</td>
    <td>NCT04343651</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Ravulizumab</td>
    <td>NCT04369469</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Nivolumab</td>
    <td>NCT04343144</td>
    <td>France</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Meplazumab</td>
    <td>NCT04275245</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td>CD24Fc</td>
    <td>NCT04317040</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>TJ003234</td>
    <td>NCT04341116</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td>IC14</td>
    <td>NCT04346277</td>
    <td>Italy</td>
    <td>Available</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>Anakinra</td>
    <td>NCT04362111</td>
    <td>UK</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Anakinra vs. siltuximab vs. tocilizumab</td>
    <td>NCT04330638</td>
    <td>Belgium</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td rowspan="6">Interferons</td>
    <td>IFN-α</td>
    <td>NTC04320236</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Interferon beta-1A</td>
    <td>NCT04350671</td>
    <td>Iran</td>
    <td>Enrolling by invitation</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td>Recombinant human interferon α1β</td>
    <td>NCT04293887</td>
    <td>China</td>
    <td>Not yet recruiting</td>
    <td>Early Phase I</td>
   </tr>
   <tr>
    <td>Recombinant human interferon alpha-1b</td>
    <td>NCT04320238</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Peginterferon lambda-1a</td>
    <td>NCT04331899</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Pegylated interferon lambda</td>
    <td>NCT04343976</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td rowspan="5">NK cells</td>
    <td rowspan="2">NK cells</td>
    <td>NCT04280224</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td>NCT04344548</td>
    <td>Colombia</td>
    <td>Not yet recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td>iPSC-derived NK cells</td>
    <td>NCT04324996</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td>IL15-NK cells vs. NKG2D CAR-NK cells vs. ACE2 CAR-NK cells vs. NKG2D-ACE2 CAR-NK cells</td>
    <td>NCT04324996</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td>CYNK-001</td>
    <td>NCT04365101</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td rowspan="15">Kinase inhibitors</td>
    <td rowspan="5">Ruxolitinib</td>
    <td>NCT04362137</td>
    <td>UK</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>NCT04348071</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td>NCT04355793</td>
    <td>USA</td>
    <td>Available</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>NCT04354714</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04377620</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td rowspan="3">Baricitinib</td>
    <td>NCT04340232</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td>NCT04358614</td>
    <td>Italy</td>
    <td>Completed</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td>NCT04346147</td>
    <td>Spain</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td rowspan="2">Acalabrutinib</td>
    <td>NCT04346199</td>
    <td>Spain</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04380688</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Duvelisib</td>
    <td>NCT04372602</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Tofacitinib</td>
    <td>NCT04332042</td>
    <td>Italy</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Imatinib</td>
    <td>NCT04346147</td>
    <td>Spain</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Ibrutinib</td>
    <td>NCT04375397</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Nintedanib</td>
    <td>NCT04338802</td>
    <td>China</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td rowspan="5">Other immunosuppressors</td>
    <td>Fingolimod</td>
    <td>NCT04280588</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Sirolimus</td>
    <td>NCT04341675</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Tacrolimus</td>
    <td>NCT04341038</td>
    <td>Spain</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Lenalidomide</td>
    <td>NCT04361643</td>
    <td>Spain</td>
    <td>Not yet recruiting</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td>Methotrexate</td>
    <td>NCT04352465</td>
    <td>Brazil</td>
    <td>Not yet recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td rowspan="24">Antivirals</td>
    <td rowspan="3">Remdesivir</td>
    <td>NCT04292899</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>NCT04280705</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>NCT04365725</td>
    <td>France</td>
    <td>Available</td>
    <td>NA</td>
   </tr>
   <tr>
    <td rowspan="3">Favipiravir</td>
    <td>NCT04336904</td>
    <td>Italy</td>
    <td>Active, not recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>NCT04346628</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04349241</td>
    <td>Egypt</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Umifenovir</td>
    <td>NCT04350684</td>
    <td>Iran</td>
    <td>Enrolling by invitation</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td>Abidol hydrochloride vs. oseltamivir vs. lopinavir/ritonavir</td>
    <td>NCT04255017</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td rowspan="4">Lopinavir/ritonavir</td>
    <td>NCT04330690</td>
    <td>Canada</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04307693</td>
    <td>Korea</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04346147</td>
    <td>Spain</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04328285</td>
    <td>France</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Galidesivir</td>
    <td>NCT03891420</td>
    <td>Brazil</td>
    <td>Recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td>Danoprevir, ritonavir</td>
    <td>NCT04345276</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td>Darunavir/cobicistat</td>
    <td>NCT04252274</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Virazole</td>
    <td>NCT04356677</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td>Clevudine</td>
    <td>NCT04347915</td>
    <td>Korea</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td rowspan="2">Nitazoxanide</td>
    <td>NCT04348409</td>
    <td>Brazil</td>
    <td>Recruiting</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>NCT04359680</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td rowspan="5">Hydroxychloroquine</td>
    <td>NCT04329611</td>
    <td>Canada</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>NCT04323631</td>
    <td>Israel</td>
    <td>Not yet recruiting</td>
    <td>Early Phase I</td>
   </tr>
   <tr>
    <td>NCT04340544</td>
    <td>Germany</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>NCT04345692</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>NCT04362332</td>
    <td>Netherlands</td>
    <td>Recruiting</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td rowspan="3">Antibiotics</td>
    <td>Azithromycin</td>
    <td>NCT04332107</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Doxycycline</td>
    <td>NCT04371952</td>
    <td>France</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Carrimycin</td>
    <td>NCT04286503</td>
    <td>China</td>
    <td>Not yet recruiting</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td rowspan="7">Decoy biomolecules</td>
    <td rowspan="2">rhACE2, rhACE2</td>
    <td>NCT04287686</td>
    <td>China</td>
    <td>Withdrawn</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>NCT04335136</td>
    <td>Austria, Denmark, Germany</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>rbACE2</td>
    <td>NCT04375046</td>
    <td>Egypt</td>
    <td>Not yet recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td rowspan="2">PUL-042, PUL-042</td>
    <td>NCT04313023</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04312997</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Rhu-pGSN</td>
    <td>NCT04358406</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Piclidenoson</td>
    <td>NCT04333472</td>
    <td>Israel</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td rowspan="5">ACE inhibitors and AR blockers</td>
    <td>Ramipril</td>
    <td>NCT04366050</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Valsartan</td>
    <td>NCT04335786</td>
    <td>Netherlands</td>
    <td>Recruiting</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td>Losartan</td>
    <td>NCT04335123</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td rowspan="2">Telmisartan</td>
    <td>NCT04355936</td>
    <td>Argentina</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04360551</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td rowspan="19">MSC and other cells</td>
    <td>Cardiosphere-derived cells</td>
    <td>NCT04338347</td>
    <td>USA</td>
    <td>Available</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>Dental pulp mesenchymal stem cells</td>
    <td>NCT04302519</td>
    <td>China</td>
    <td>Not yet recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td>Dental pulp stem cells</td>
    <td>NCT04336254</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td>MSC exosomes</td>
    <td>NCT04276987</td>
    <td>China</td>
    <td>Not yet recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td rowspan="3">MSC</td>
    <td>NCT04252118</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td>NCT04361942</td>
    <td>Spain</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04377334</td>
    <td>Germany</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td rowspan="3">AD MSC</td>
    <td>NCT04362189</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04352803</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td>NCT04366323</td>
    <td>Spain</td>
    <td>Not yet recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td rowspan="2">BM-MSC</td>
    <td>NCT04346368</td>
    <td>China</td>
    <td>Not yet recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td>NCT04345601</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Early Phase I</td>
   </tr>
   <tr>
    <td rowspan="6">UC-MSC</td>
    <td>NCT04355728</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td>NCT04273646</td>
    <td>China</td>
    <td>Not yet recruiting</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>NCT04333368</td>
    <td>France</td>
    <td>Recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td>NCT04269525</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04339660</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td>NCT04366271</td>
    <td>Spain</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>WJ-MSC</td>
    <td>NCT04313322</td>
    <td>Jordan</td>
    <td>Recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td rowspan="10">Corticosteroids</td>
    <td rowspan="2">Ciclesonide</td>
    <td>NCT04330586</td>
    <td>Korea</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04381364</td>
    <td>Sweden</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Budesonide</td>
    <td>NCT04355637</td>
    <td>Spain</td>
    <td>Recruiting</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td rowspan="2">Dexamethasone</td>
    <td>NCT04325061</td>
    <td>Spain</td>
    <td>Not yet recruiting</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td>NCT04360876</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Prednisone</td>
    <td>NCT04344288</td>
    <td>France</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Prednisone vs. hydrocortisone</td>
    <td>NCT04359511</td>
    <td>France</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td rowspan="2">Methylprednisolone</td>
    <td>NCT04273321</td>
    <td>China</td>
    <td>Suspended</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>NCT04274071</td>
    <td>USA</td>
    <td>Completed</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>Methylprednisolone sodium succinate</td>
    <td>NCT04343729</td>
    <td>Brazil</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td rowspan="6">Sedatives, antidepressants, neuroleptics</td>
    <td rowspan="2">Chlorpromazine</td>
    <td>NCT04366739</td>
    <td>France</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>NCT04354805</td>
    <td>Egypt</td>
    <td>Not yet recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td>Thalidomide</td>
    <td>NCT04273529</td>
    <td>China</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Fluvoxamine</td>
    <td>NCT04342663</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Fluoxetine</td>
    <td>NCT04377308</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td>Dexmedetomidine</td>
    <td>NCT04358627</td>
    <td>Spain</td>
    <td>Not yet recruiting</td>
    <td>NA</td>
   </tr>
   <tr>
    <td rowspan="30">Others</td>
    <td>Azoximer bromide</td>
    <td>NCT0438177</td>
    <td>Russia</td>
    <td>Recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td>Etoposide</td>
    <td>NCT04356690</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Bicalutamide</td>
    <td>NCT04374279</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Selinexor</td>
    <td>NCT04349098</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Melphalan</td>
    <td>NCT04380376</td>
    <td>Russia</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Bromhexine</td>
    <td>NCT04355026</td>
    <td>Slovenia</td>
    <td>Recruiting</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td>
     <italic>N</italic>-acetylcysteine
    </td>
    <td>NCT04374461</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td>Sargramostim</td>
    <td>NCT04326920</td>
    <td>Belgium</td>
    <td>Recruiting</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td>Angiotensin peptide (1-7) derived plasma</td>
    <td>NCT04375124</td>
    <td>Turkey</td>
    <td>Recruiting</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>Defibrotide</td>
    <td>NCT04335201</td>
    <td>Italy</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Aviptadil</td>
    <td>NCT04311697</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Dornase alpha</td>
    <td>NCT04355364</td>
    <td>France</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Nafamostat mesilate</td>
    <td>NCT04352400</td>
    <td>Italy</td>
    <td>Not yet recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td rowspan="2">Camostat mesilate</td>
    <td>NCT04321096</td>
    <td>Denmark</td>
    <td>Not yet recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td>NCT04353284</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Almitrine</td>
    <td>NCT04357457</td>
    <td>France</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Sildenafil citrate</td>
    <td>NCT04304313</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Progesterone</td>
    <td>NCT04365127</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td rowspan="2">Colchicine</td>
    <td>NCT04375202</td>
    <td>Italy</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04355143</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Tetrandrine</td>
    <td>NCT04308317</td>
    <td>China</td>
    <td>Enrolling by invitation</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td>Vazegepant</td>
    <td>NCT04346615</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td>Dapagliflozin</td>
    <td>NCT04350593</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Isotretinoin</td>
    <td>NCT04361422</td>
    <td>Egypt</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Deferoxamine</td>
    <td>NCT04333550</td>
    <td>Iran</td>
    <td>Recruiting</td>
    <td>Phase I/II</td>
   </tr>
   <tr>
    <td>SnPP protoporphyrin</td>
    <td>NCT04371822</td>
    <td>Egypt</td>
    <td>Not yet recruiting</td>
    <td>Phase I</td>
   </tr>
   <tr>
    <td>Ascorbic acid</td>
    <td>NCT04363216</td>
    <td>USA</td>
    <td>Not yet recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>BACTEK-R</td>
    <td>NCT04363814</td>
    <td>Spain</td>
    <td>Not yet Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Traditional Chinese medicine</td>
    <td>NCT04323332</td>
    <td>China</td>
    <td>Not yet recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Huaier granule</td>
    <td>NCT04291053</td>
    <td>China</td>
    <td>Not yet recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td rowspan="13">Combined</td>
    <td rowspan="2">Favipiravir, hydroxychloroquine</td>
    <td>NCT04359615</td>
    <td>Iran</td>
    <td>Not yet recruiting</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td>NCT04376814</td>
    <td>Iran</td>
    <td>Enrolling by invitation</td>
    <td>NA</td>
   </tr>
   <tr>
    <td>Favipiravir, tocilizumab</td>
    <td>NCT04310228</td>
    <td>China</td>
    <td>Recruiting</td>
    <td>NA</td>
   </tr>
   <tr>
    <td rowspan="3">Hydroxychloroquine, azithromycin</td>
    <td>
     <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT04328272" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04328272</ext-link>
    </td>
    <td>Pakistan</td>
    <td>Not yet Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>NCT04329832</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>NCT04359316</td>
    <td>Iran</td>
    <td>Not yet recruiting</td>
    <td>Phase IV</td>
   </tr>
   <tr>
    <td>Hydroxychloroquine, nitazoxanide</td>
    <td>NCT04361318</td>
    <td>Egypt</td>
    <td>Not yet recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td>Hydroxychloroquine, azithromycin, tocilizumab</td>
    <td>NCT04332094</td>
    <td>Spain</td>
    <td>Recruiting</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Hydroxychloroquine vs. hydroxychloroquine, lopinavir/ritonavir vs. hydroxychloroquine, azithromycin</td>
    <td>NCT04359095</td>
    <td>Colombia</td>
    <td>Not yet recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td>Hydroxychloroquine, famotidine</td>
    <td>NCT04370262</td>
    <td>USA</td>
    <td>Recruiting</td>
    <td>Phase III</td>
   </tr>
   <tr>
    <td>Ivermectin, Nitazoxanide</td>
    <td>NCT04360356</td>
    <td>Egypt</td>
    <td>Not yet recruiting</td>
    <td>Phase II/III</td>
   </tr>
   <tr>
    <td>Lopinavir/ritonavir, ribavirin, interferon beta-1B</td>
    <td>NCT04276688</td>
    <td>China</td>
    <td>Completed</td>
    <td>Phase II</td>
   </tr>
   <tr>
    <td>Met-enkephalin, tridecactide</td>
    <td>NCT04374032</td>
    <td>Bosnia and Herzegovina</td>
    <td>Recruiting</td>
    <td>Phase II/III</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>ACE</italic> angiotensin-converting enzyme; 
   <italic>AR</italic> angiotensin receptor; 
   <italic>DFPP</italic> double-filtration plasmapheresis; 
   <italic>MSC</italic> mesenchymal stem (stromal) cells; 
   <italic>AD MSC</italic> adipose-derived MSC; 
   <italic>BM-MSC</italic> bone marrow–derived MSC; 
   <italic>UC-MSC</italic> umbilical cord–derived MSC; 
   <italic>WJ-MSC</italic> Wharton jelly–derived MSC; 
   <italic>NK cells</italic> natural killer cells; 
   <italic>rhACE2</italic> recombinant human angiotensin-converting enzyme 2; 
   <italic>rbACE2</italic> recombinant bacterial angiotensin-converting enzyme 2; 
   <italic>Rhu-pGSN</italic> recombinant human plasma gelsolin
  </p>
 </table-wrap-foot>
</table-wrap>
